Please Wait
Applying Filters...
menu
    • menu
    Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    ADUHELM

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Acumen Shows pTau217 Assay Utility in Ph2 Alzheimer’s Trial
    Acumen Shows pTau217 Assay Utility in Ph2 Alzheimer’s Trial

    28 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/28/3122403/0/en/Acumen-Pharmaceuticals-Presents-Studies-Showing-the-Utility-of-a-pTau217-Assay-in-Screening-for-a-Phase-2-Alzheimer-s-Disease-Trial-and-Validates-Sabirnetug-Oligomer-Selectivity-at.html

    GLOBENEWSWIRE
    28 Jul 2025
    Share Share
    Biogen in up to $1.8 bln deal as rare diseases take center stage
    Biogen in up to $1.8 bln deal as rare diseases take center stage

    23 May 2024

    // REUTERS

    https://www.reuters.com/markets/deals/biogen-buy-human-immunology-biosciences-up-18-bln-deal-2024-05-22/

    REUTERS
    23 May 2024
    Share Share
    FDA revises guidance on predicting Alzheimer's drug benefits
    FDA revises guidance on predicting Alzheimer's drug benefits

    12 Mar 2024

    // Gabrielle Masson FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/new-fda-guidelines-consider-amyloid-reduction-reasonably-likely-predict-clinical-benefit

    Gabrielle Masson FIERCE BIOTECH
    12 Mar 2024
    Share Share
    Biogen drops Alzheimer's drug Aduhelm, ending a 17-year chapter
    Biogen drops Alzheimer's drug Aduhelm, ending a 17-year chapter

    01 Feb 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/biogen-discontinue-development-older-alzheimers-drug-aduhelm-2024-01-31/

    REUTERS
    01 Feb 2024
    Share Share
    Biogen comes out ahead in Aduhelm-related investor lawsuit
    Biogen comes out ahead in Aduhelm-related investor lawsuit

    31 Mar 2023

    // Zoey Becker FIERCE PHARMA

    https://www.fiercepharma.com/pharma/biogen-scores-win-massachusetts-judge-dismisses-investor-lawsuit

    Zoey Becker FIERCE PHARMA
    31 Mar 2023
    Share Share
    VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
    VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm

    14 Mar 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/va-to-cover-eisais-new-alzheimers-drug-after-declining-to-cover-aduhelm/

    Zachary Brennan ENDPTS
    14 Mar 2023
    Share Share